Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in a Series A+ financing round led by Bayland Capital, a joint biomedical fund established by Contract Research Organization (CRO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) and Legend Capital. The round included participation from Tailong Venture Capital, Morimatsu Pharma, Simbay Group, and Long Hill Capital.
Funding Details
Proceeds will fund the development of Lab Direct’s own brands, CMC (Chemistry, Manufacturing, and Controls)-compliant manufacturing materials, and digital platform construction. The company aims to enhance its supply chain solutions for the life sciences sector.
Company Profile
Founded in 2014, Lab Direct offers a Supply Procurement Management (SPM) integrated service, partnering with local industrial parks to establish a “green channel” for biomaterials and special goods. It is exploring opportunities in the cell and gene therapy (CGT) market, focusing on GMP-compliant materials and supplies.
Strategic Outlook
The funding will support Lab Direct’s expansion into high-growth areas, including CGT and digital supply chain innovation, leveraging its partnerships and integrated SPM platform.-Fineline Info & Tech
